Skip to main content
Log in

Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats

Basic Research in Cardiology Aims and scope Submit manuscript

Abstract

Mesenchymal stem cells (MSCs) are the pluripotent cells, which enter the circulation and home to sites of tissue injury or inflammation. MSCs are highlighted as a potential cell vector for gene therapy. In this study, we investigated whether transplanted allogeneic MSCs preferentially accumulate in the lung in rats with pulmonary hypertension (PH) and if so to determine the efficacy of MSC-based prostacyclin synthase (PCS) gene therapy for PH. PH was induced in Lewis rats by injecting monocrotaline at 7-weeks-old (week 0). MSCs were obtained by culturing bone marrow mononuclear cells. Allogeneic MSCs were intravenously transplanted at week 2 when moderate PH had been established. PH enhanced indium-111-oxine-labeled MSC accumulation in the lungs, but not in other organs, 2.5-times and 6-times, 1 and 14 days after transplantation, respectively. Transplantation of MSCs transduced with PCS (PSC-MSCs), but not with GFP (GFP-MSCs), reduced PH, pulmonary arterial thickening, and RV hypertrophy at week 4. The lung prostacyclin production was impaired in PH rats, which was restored and maintained for long time by PCS-MSCs, but not by GFP-MSCs. The survival rate at week 7 was 100% in PCS-MSC-transplanted PH rats, whereas they were 38 and 44% in PH rats and GFP-MSC-transplanted PH rats, respectively. In conclusion, the gene-engineered MSCs would be a suitable cell vector for gene delivery specifically to the PH lung. The allogeneic PCS-MSC transplantation attenuated PH and cardiovascular remodeling, and improved the prognosis in PH rats. The MSC-based PCS gene therapy may be a promising strategy for PH treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Abedin M, Tintut Y, Demer LL (2004) Mesenchymal stem cells and the artery wall. Circ Res 95:671–676

    Article  CAS  PubMed  Google Scholar 

  2. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410–2413

    Article  CAS  PubMed  Google Scholar 

  3. Baksh D, Song L, Tuan RS (2004) Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8:301–316

    Article  CAS  PubMed  Google Scholar 

  4. Campbell AI, Kuliszewski MA, Stewart DJ (1999) Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 21:567–575

    CAS  PubMed  Google Scholar 

  5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672

    Article  CAS  PubMed  Google Scholar 

  6. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70–75

    CAS  PubMed  Google Scholar 

  7. Correia-Pinto J, Henriques-Coelho T, Roncon-Albuquerque R Jr, Lourenço AP, Melo-Rocha G, Vasques-Nóvoa F, Gillebert TC, Leite-Moreira AF (2009) Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension. Basic Res Cardiol 104:535–575

    Article  PubMed  Google Scholar 

  8. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12–20

    Article  CAS  PubMed  Google Scholar 

  9. Halkos ME, Zhao Z-Q, Kerendi F, Wang N-P, Jiang R, Schmarkey LS, Martin BJ, Quyyumi AA, Few WL, Kin H, Guyton RA, Vnten-Johansen J (2008) Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 103:525–536

    Article  PubMed  Google Scholar 

  10. Hirschi KK, Goodell MA (2002) Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther 9:648–652

    Article  CAS  PubMed  Google Scholar 

  11. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425–1436

    Article  CAS  PubMed  Google Scholar 

  12. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH (2006) Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81:1589–1595

    Article  PubMed  Google Scholar 

  13. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, Katsumata T (2006) Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114:I181–I185

    PubMed  Google Scholar 

  14. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, Fine A (2001) Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 128:5181–5188

    CAS  PubMed  Google Scholar 

  15. Lambert RR, Vaessen RJ, Waterhof N, Stienen GJM (2007) Right ventricular hypertrophy causes impairment of leftventricular diastolic function in the rat. Basic Res Cardiol 102:19–27

    Article  CAS  Google Scholar 

  16. Lappin PB, Ross KL, King LE, Fraker PJ, Roth RA (1998) The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo. Toxicol Appl Pharmacol 150:37–48

    Article  CAS  PubMed  Google Scholar 

  17. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6:1282–1286

    Article  CAS  PubMed  Google Scholar 

  18. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195–1201

    Article  CAS  PubMed  Google Scholar 

  19. Mullane KM, Dusting GJ, Salmon JA, Moncada S, Vane JR (1979) Biotransformation and cardiovascular effects of arachidonic acid in the dog. Eur J Pharmacol 54:217–228

    Article  CAS  PubMed  Google Scholar 

  20. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara T, Hara H, Mori H (2003) Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108:889–895

    Article  CAS  PubMed  Google Scholar 

  21. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T (2000) Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102:2005–2010

    CAS  PubMed  Google Scholar 

  22. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147

    Article  CAS  PubMed  Google Scholar 

  23. Pittenger MF, Martin BJ (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95:9–20

    Article  CAS  PubMed  Google Scholar 

  24. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL (2005) Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 33:145–152

    Article  CAS  PubMed  Google Scholar 

  25. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM (2002) Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 109:1291–1302

    CAS  PubMed  Google Scholar 

  26. Suhara H, Sawa Y, Fukushima N, Kagisaki K, Yokoyama C, Tanabe T, Ohtake S, Matsuda H (2002) Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. J Thorac Cardiovasc Surg 123:855–861

    Article  CAS  PubMed  Google Scholar 

  27. Tahara N, Kai H, Niiyama H, Mori T, Sugi Y, Takayama N, Yasukawa H, Numaguchi Y, Matsui H, Okumura K, Imaizumi T (2004) Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 15:1270–1278

    Article  CAS  PubMed  Google Scholar 

  28. Tone Y, Inoue H, Hara S, Yokoyama C, Hatae T, Oida H, Narumiya S, Shigemoto R, Yukawa S, Tanabe T (1997) The regional distribution and cellular localization of mRNA encoding rat prostacyclin synthase. Eur J Cell Biol 72:268–277

    CAS  PubMed  Google Scholar 

  29. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159:1925–1932

    CAS  PubMed  Google Scholar 

  30. Vane JR, Anggard EE, Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27–36

    Article  CAS  PubMed  Google Scholar 

  31. Vonk MC, van Dijk AP, Heijdra YF, van der Heijden HF, Bredie SJ, van den Hoogen FH (2005) Pulmonary hypertension: its diagnosis and management, a multidisciplinary approach. Neth J Med 63:193–198

    CAS  PubMed  Google Scholar 

  32. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Zhu JH, Chen JZ (2007) Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49:1566–1571

    Article  CAS  PubMed  Google Scholar 

  33. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96:442–450

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Kimiko Kimura, Yayoi Yoshida, Reiko Fujiyoshi, Michiko Taguchi, Miyuki Ohuchida, and Miho Kogure for their skilful technical assistance. This study was supported in part by a grant for the Science Frontier Research Promotion Centers; by Grants-In-Aid for Scientific Research (HK, NT, TI) from the Ministry of Education, Science, Sports and Culture, Japan; and by a research grant from Kimura Memorial Heart Foundation (TI).

Conflict of interest statement

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hisashi Kai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takemiya, K., Kai, H., Yasukawa, H. et al. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 105, 409–417 (2010). https://doi.org/10.1007/s00395-009-0065-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00395-009-0065-8

Keywords

Navigation